Supporting Information

Regio- and stereoselective C-H alkenylation of pyridines with silyl-substituted alkynes by half-sandwich scandium catalyst

Wei Zhou,^a Shuya Wang,^b Masayoshi Nishiura,^{a,c} Xuefeng Cong*,^b, Zhaomin Hou *,a,c

^aAdvanced Catalysis Research Group, RIKEN Center for Sustainable Resource Science, Wako, Saitama, Japan.

^bInstitute of Molecular Plus, Haihe Laboratory of Sustainable Chemical Transformations, Tianjin University, Tianjin, China.

^cOrganometallic Chemistry Laboratory, RIKEN Cluster for Pioneering Research, Wako, Saitama, Japan.

E-mail: xuefengcong@tju.edu.cn; houz@riken.jp

Table of Contents

I. General information II. General procedure for the Sc-catalyzed alkenylation of pyridines with silylated alkynes III. Analytic data for synthesized compounds	2	
	2	
	3	
IV NMR spectra	24	

I. General information

All manipulations of air- and moisture-sensitive compounds were performed under dry nitrogen atmosphere in an mBRAUN Labmaster glovebox. Nitrogen was purified by being passed through a dry column (4 Å molecular sieves, Nikka Seiko Co.) and a Gasclean GC-XR column (Nikka Seiko Co.). The nitrogen in the glovebox was constantly circulated through a copper/molecular sieves catalyst unit. The oxygen and moisture concentrations in the glovebox atmosphere were monitored by an O₂/H₂O Combi-Analyzer (Mbraun) to ensure both were always below 0.1 ppm. Solvents (THF, Hexane and Toluene) (dehydrated, stabilizer-free) were obtained from Kanto Kagaku Co., purified by an mBRAUN SPS-800 solvent purification system, and dried over fresh Na chips in a glovebox. The commercially available alkynes and pyridines were obtained from Tokyo Chemical Industry Co., Ltd., dried with CaH₂ before use. Other silylated alkynes were prepared from corresponding literatures. Half-sandwich complexes Sc-1~Sc-4, Y-4 and Lu-4 were also prepared according to the literature procedure.² Silica gel column chromatography was performed with Silica Gel 60 N (spherical, neutral, 40-50 µm) obtained from Kanato Chemical Co. All ¹H NMR and ¹³C NMR spectra of organic products were recorded on Bruker AVANCE III HD 500 NMR (500 MHz) instrument. The ¹H NMR Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as standard. The ¹³C NMR chemical shifts were given using CDCl₃ (77.16 ppm) as the internal standard. The data are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, coupling constant(s) in Hz, integration). High Resolution Mass Spectra were obtained on a Bruker microTOF-Q III (ESI⁺).

II. General procedure for the Sc-catalyzed alkenylation of pyridines with silylated alkynes

In a glovebox, $[Ph_3C][B(C_6F_5)_4]$ (13.8 mg, 0.015 mmol in 0.5 mL toluene) was added to a stirred toluene solution (1.5 mL) of **Sc-4** (7.2 mg, 0.015 mmol) in a Schlenk tube. After 10 min, to this tube was added pyridines **1** (0.2 mmol) and alkynes **2** (0.4 mmol). After that, the tube was sealed, taken outside, and stirred at 70 °C for 12 h. Then, the mixture was concentrated and purified by silica gel column chromatography (hexane/ethyl acetate = 4:1) to obtain the desired product **3**. The E/Z ratio (>19:1) and regioisomeric ratio (r.r.) (>19:1) were determined by NMR analysis of the crude reaction mixture.

III. Analytic data for synthesized compounds

(E)-2-Methyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3a)

The title compound was prepared according to the general procedure as a white solid (52.5 mg, 98% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.40–7.33 (m, 4H), 7.27 (s, 1H), 7.27–7.23 (m, 2H), 6.99 (d, J = 7.5 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 2.61 (s, 3H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 157.91, 157.03, 155.26, 141.56, 136.48, 132.68, 129.80, 127.98, 127.32, 121.86, 119.37, 24.82, -0.16; HRMS (ESI) m/z calcd. for $C_{17}H_{22}NSi$ [M+H] $^{+}$ = 268.1516, found = 268.1518.

(*E*)-2-Butyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3b)

The title compound was prepared according to the general procedure as a white solid (55.6 mg, 86% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.41–7.34 (m, 4H), 7.26–7.24 (m, 3H), 6.99 (d, J = 7.5 Hz, 1H), 6.67 (d, J = 7.5 Hz, 1H), 2.84 (t, J = 7.5 Hz, 2H), 1.82–1.76 (m, 2H), 1.40–1.38 (m, 4H), 0.92 (d, J = 7.0 Hz, 3H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 161.93, 156.96, 155.39, 141.67, 136.38, 132.62, 129.82,

127.95, 127.28, 121.18, 119.46, 38.49, 31.67, 29.29, 22.56, 14.05, -0.14; HRMS (ESI) m/z calcd. for $C_{21}H_{30}NSi\ [M+H]^+ = 324.2142$, found = 324.2147.

(*E*)-2-Benzyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3c)

The title compound was prepared according to the general procedure as a white solid (66.4 mg, 94% yield) ¹H NMR $(500 \text{ MHz}, \text{CDCl}_3)$: $\delta 7.38-7.34 \text{ (m, 4H)}, 7.32-7.30 \text{ (m, 5H)}, 7.25-7.21 \text{ (m, 3H)}, 6.89 \text{ (d, } \textit{J} = 7.5 \text{ Hz}, 1\text{H)}, 6.70 \text{ (d, } \textit{J} = 8.0 \text{ Hz}, 1\text{H)}, 4.22 \text{ (s, 3H)}, -0.10 \text{ (s, 9H)};$ ¹³C NMR $(125 \text{ MHz}, \text{CDCl}_3)$: $\delta 160.40, 157.08, 155.21, 141.54, 139.62, 136.71, 133.03, 129.81, 129.35, 128.47, 127.98, 127.33, 126.28, 121.47, 119.71, 44.94, -0.15; HRMS (ESI) m/z calcd. for <math>C_{23}H_{26}NSi \text{ [M+H]}^+ = 344.1829$, found = 344.1832.

(E)-2-Chloro-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3d)

The title compound was prepared according to the general procedure as a white solid (54.0 mg, 94% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.47–7.44 (m, 1H), 7.41–7.36 (m, 3H), 7.32 (s, 1H), 7.23–7.21 (m, 2H), 7.15 (d, J = 7.5 Hz, 1H), 6.77 (d, J = 7.5 Hz, 1H), - 0.1 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.45, 153.14, 151.02, 140.64, 138.95, 135.16, 129.72, 128.19, 127.63, 122.55, 120.49, -0.31; HRMS (ESI) m/z calcd. for $C_{16}H_{19}CINSi[M+H]^{+}$ = 288.0970, found = 288.0968.

(E)-2-Bromo-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3e)

The title compound was prepared according to the general procedure as a white solid (60.2 mg, 91% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.40–7.35 (m, 3H), 7.34–7.29 (m, 3H), 7.22–7.20 (m, 2H), 6.79 (d, J = 7.5 Hz, 1H), -0.12 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.00, 153.01, 141.93, 140.55, 138.64, 135.31, 129.71, 128.20,

127.64, 126.31, 120.81, -0.31; HRMS (ESI) m/z calcd. for $C_{16}H_{19}BrNSi\ [M+H]^+ = 332.0465$, found = 332.0466.

(*E*)-2-Iodo-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3f)

The title compound was prepared according to the general procedure as a white solid (72.8 mg, 96% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.53 (d, J = 8.0 Hz, 1H), 7.40–7.36 (m, 3H), 7.30 (s, 1H), 7.22–7.20 (m, 2H), 7.12–7.09 (m, 1H), 6.79 (d, J = 7.5 Hz, 1H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.56, 153.09, 140.48, 137.69, 135.20, 133.09, 129.71, 128.20, 127.62, 121.17, 118.27, -0.29; HRMS (ESI) m/z calcd. for $C_{16}H_{19}INSi[M+H]^{+}$ = 380.0326, found = 380.0331.

(E)-2-(1-Phenyl-2-(trimethylsilyl)vinyl)-6-(3-phenylpropyl)pyridine (3g)

The title compound was prepared according to the general procedure as a white solid (69.0 mg, 93% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.42–7.34 (m, 4H), 7.31–7.28 (m, 3H), 7.25–7.23 (m, 4H), 7.20–7.17 (m, 1H), 6.98 (d, J = 7.5 Hz, 1H), 6.70 (d, J = 7.5 Hz, 1H), 2.88 (t, J = 7.5 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H), 2.17–2.11 (m, 2H), 0.92 (d, J = 7.0 Hz, 3H), -0.10 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 161.27, 157.07, 155.37, 142.37, 141.63, 136.45, 132.73, 129.81, 128.54, 128.27, 127.96, 127.30, 125.70, 121.31, 119.57, 37.81, 35.47, 31.04, -0.14; HRMS (ESI) m/z calcd. for $C_{25}H_{30}NSi$ [M+H] $^{+}$ = 372.2142, found = 372.2145.

(E)-2-(1-Phenyl-2-(trimethylsilyl)vinyl)-6-(3-(pyridin-2-yl)propyl)pyridine (3h)

The title compound was prepared according to the general procedure as a white solid (58.8 mg, 79% yield). ¹H NMR (500 MHz, CDCl₃): δ 8.53 (d, J = 4.5 Hz, 1H), 7.61–

7.57 (m, 1H), 7.42–7.34 (m, 4H), 7.27–7.23 (m, 3H), 7.19 (d, J = 7.5 Hz, 1H), 7.12–7.09 (m, 1H), 7.01 (d, J = 8.0 Hz, 1H), 6.70 (d, J = 7.5 Hz, 1H), 2.92–2.89 (m, 4H), 2.27–2.21 (m, 2H), -0.10 (s, 9H); ¹³C NMR (125 MHz, CDCl₃): δ 161.95, 161.13, 157.03, 155.34, 149.18, 141.61, 136.48, 136.23, 132.67, 129.79, 127.94, 127.27, 122.95, 121.34, 120.95, 119.59, 37.85, 37.80, 29.51, -0.16; HRMS (ESI) m/z calcd. for $C_{24}H_{29}N_2Si[M+H]^+$ = 373.2095, found = 373.2091.

(*E*)-5-Methyl-2-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3i)

The title compound was prepared according to the general procedure as a white solid (44.9 mg, 84% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.46 (s, 1H), 7.39–7.31 (m, 4H), 7.24–7.22 (m, 2H), 7.09 (s, 1H), 6.84 (d, J = 8.0 Hz, 1H), 2.31 (s, 3H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 155.63, 155.14, 149.68, 141.60, 136.73, 132.01, 131.71, 129.73, 128.00, 127.35, 121.76, 18.11, -0.20; HRMS (ESI) m/z calcd. for C₁₇H₂₂NSi [M+H] $^{+}$ = 268.1516, found = 268.1518.

(S,E)-5-(1-Methylpyrrolidin-2-yl)-2-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3j)

The title compound was prepared according to the general procedure as a white solid (49.7 mg, 74% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.55 (s, 1H), 7.54–7.52 (m, 1H), 7.40–7.34 (m, 3H), 7.25–7.24 (m, 2H), 7.16 (s, 2H), 6.92 (d, J = 8.0 Hz, 1H), 3.22 (t, J = 9.0 Hz, 1H), 3.08 (t, J = 8.0 Hz, 1H), 2.32–2.26 (m, 1H), 2.21–2.14 (m, 4H), 1.99–1.90 (m, 1H), 1.84–1.77 (m, 1H), 1.74–1.66 (m, 1H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 157.14, 155.08, 149.05, 141.48, 137.23, 135.16, 132.65, 129.73, 128.03, 127.39, 122.14, 68.65, 56.97, 40.31, 35.11, 22.51, -0.23; HRMS (ESI) m/z calcd. for $C_{21}H_{29}N_{2}Si$ [M+H] $^{+}$ = 337.2095, found = 337.2032.

(E)-2,4-Dimethyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3k)

The title compound was prepared according to the general procedure as a white solid (50.6 mg, 90% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.39–7.33 (m, 3H), 7.26–7.22 (m, 3H), 6.84 (s, 1H), 6.50 (s, 1H), 2.56 (s, 3H), 2.15 (s, 3H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 157.68, 157.11, 155.41, 147.42, 141.67, 132.67, 129.80, 127.93, 127.26, 122.84, 120.48, 24.57, 20.88, -0.16; HRMS (ESI) m/z calcd. for C₁₈H₂₄NSi [M+H] $^{+}$ = 282.1673, found = 282.1677.

(E)-4-Chloro-2-methyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3l)

The title compound was prepared according to the general procedure as a white solid (57.2 mg, 95% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.41–7.37 (m, 3H), 7.29 (s, 1H), 7.23–7.21 (m, 2H), 7.03 (s, 1H), 6.68 (s, 1H), 2.58 (s, 3H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.22, 158.67, 154.10, 144.38, 140.72, 134.75, 129.73, 128.19, 127.64, 121.78, 119.64, 24.60, -0.27; HRMS (ESI) m/z calcd. for C_{17} H₂₁NClSi [M+H] $^{+}$ = 302.1126, found = 302.1128.

(E)-4-Bromo-2-methyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3m)

The title compound was prepared according to the general procedure as a white solid (66.2 mg, 96% yield). ¹H NMR $(500 \text{ MHz}, \text{CDCl}_3)$: δ 7.41–7.37 (m, 3H), 7.27 (s, 1H), 7.23–7.20 (m, 3H), 6.84 (s, 1H), 2.58 (s, 3H), -0.11 (s, 9H); ¹³C NMR $(125 \text{ MHz}, \text{CDCl}_3)$: δ 159.11, 158.54, 154.02, 140.68, 134.88, 133.28, 129.72, 128.19, 127.65,

124.80, 122.53, 24.51, -0.27; HRMS (ESI) m/z calcd. for $C_{17}H_{21}NBrSi~[M+H]^{+} = 346.0621$, found = 346.0625.

(*E*)-2,3-Dimethyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3n)

The title compound was prepared according to the general procedure as a white solid (48.9 mg, 87% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.32–7.38 (m, 3H), 7.25–7.19 (m, 4H), 6.60 (d, J = 8.0 Hz, 1H), 2.56 (s, 3H), 2.24 (s, 3H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 156.60, 155.22, 154.63, 141.71, 137.22, 131.32, 130.18, 129.79, 127.91, 127.22, 119.87, 23.07, 18.84, -0.13; HRMS (ESI) m/z calcd. for C₁₈H₂₄NSi [M+H] $^{+}$ = 282.1673, found = 282.1677.

(E)-3-Bromo-2-methyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (30)

The title compound was prepared according to the general procedure as a white solid (55.2 mg, 80% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.59 (d, J = 8.0 Hz, 1H), 7.39–7.35 (m, 3H), 7.25 (s, 1H), 7.22–7.21 (m, 2H), 6.57 (d, J = 8.0 Hz, 1H), 2.71 (s, 3H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 156.51, 155.87, 154.18, 141.05, 139.86, 133.70, 129.70, 128.11, 127.53, 121.02, 120.13, 25.31, -0.26; HRMS (ESI) m/z calcd. for $C_{17}H_{21}NBrSi$ [M+H] $^{+}$ = 346.0621, found = 346.0625.

(E)-2-Bromo-3-methoxy-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3p)

The title compound was prepared according to the general procedure as a white solid (57.8 mg, 80% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.39–7.34 (m, 3H), 7.21–7.20 (m, 1H), 7.14 (s, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 7.5 Hz, 1H), 3.86 (s, 3H), -0.13 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 152.59, 151.61, 150.72, 140.99, 132.40,

132.25, 129.69, 128.12, 127.50, 121.86, 118.23, 56.27, -0.22; HRMS (ESI) m/z calcd. for $C_{17}H_{21}NOBrSi [M+H]^+ = 362.0570$, found = 362.0571.

(*E*)-2,3,5-Trimethyl-6-(1-phenyl-2-(trimethylsilyl)vinyl)pyridine (3q)

The title compound was prepared according to the general procedure as a white solid (41.8 mg, 72% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.09–7.08 (m, 2H), 7.05–7.00 (m, 3H), 6.92 (s, 1H), 2.23 (s, 3H), 1.99 (s, 3H), 1.83 (s, 3H), -0.23 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.64, 156.94, 153.41, 142.04, 139.58, 133.81, 129.56, 128.77, 127.64, 127.35, 127.29, 22.19, 19.02, 18.65, -0.21; HRMS (ESI) m/z calcd. for C₉H₂₅NSi [M+H] $^{+}$ = 295.1756, found = 295.1758.

(E)-2-(1-Phenyl-2-(trimethylsilyl)vinyl)-6,7-dihydro-5H-cyclopenta[b]pyridine (3 r)

The title compound was prepared according to the general procedure as a white solid (53.1 mg, 91% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.38–7.34 (m, 3H), 7.29 (d, J = 7.5 Hz, 1H), 7.25–7.23 (m, 2H), 7.19 (s, 1H), 3.06 (s, J = 7.5 Hz, 2H), 2.89 (s, J = 7.5 Hz, 2H), 2.18–2.10 (m, 2H), -0.11 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 156.59, 156.23, 155.42, 141.91, 135.79, 131.93, 131.46, 129.77, 127.94, 127.23, 120.11, 34.43, 30.42, 23.35, -0.13; HRMS (ESI) m/z calcd. for C₁₉H₂₃NSi [M+H] $^{+}$ = 293.1600, found = 293.1601.

(E)-2-(1-Phenyl-2-(trimethylsilyl)vinyl)-5,6,7,8-tetrahydroquinoline (3s)

The title compound was prepared according to the general procedure as a white solid (54.9 mg, 94% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.38–7.33 (m, 3H), 7.24–7.23

(m, 2H), 7.17–7.16 (m, 2H), 6.61 (d, J = 8.0 Hz, 1H), 2.98 (t, J = 6.5 Hz, 2H), 2.73 (t, J = 6.5 Hz, 2H), 1.93–1.88 (m, 2H), 1.83–1.78 (m, 2H), -0.11 (s, 9H); ¹³C NMR (125 MHz, CDCl₃): δ 156.91, 155.32, 154.93, 141.74, 136.89, 131.63, 131.13, 129.80, 127.93, 127.24, 119.73, 32.97, 28.53, 23.18, 22.79, -0.12; HRMS (ESI) m/z calcd. for $C_{20}H_{25}NSi[M+H]^+$ = 293.1600, found = 293.1601.

(E)-2-(1-Phenyl-2-(trimethylsilyl)vinyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyri dine (3t)

The title compound was prepared according to the general procedure as a white solid (59.0 mg, 92% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.38–7.32 (m, 3H), 7.25–7.24 (m, 3H), 7.17 (d, J = 8.0 Hz, 1H), 6.56 (d, J = 8.0 Hz, 1H), 3.11 (t, J = 5.0 Hz, 2H), 2.73 (t, J = 4.0 Hz, 2H), 1.89–1.85 (m, 2H), 1.75–1.73 (m, 2H), 1.65–1.64 (m, 2H), 0.12 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 162.73, 155.25, 154.25, 141.75, 136.92, 136.68, 131.42, 129.81, 127.91, 127.21, 119.79, 39.86, 35.02, 32.54, 28.12, 26.73, 0.11; HRMS (ESI) m/z calcd. for $C_{21}H_{27}NSi$ [M+H] $^{+}$ = 321.1913, found = 321.1914.

(E)-1-Methyl-3-(1-phenyl-2-(trimethylsilyl)vinyl)isoquinoline (3u)

The title compound was prepared according to the general procedure as a white solid (56.2 mg, 89% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.08 (d, J = 8.0 Hz, 1H), 7.59–7.50 (m, 4H), 7.46–7.40 (m, 3H), 7.34–7.32 (m, 2H), 7.02 (s, 1H), 3.04 (s, 3H), -0.06 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.15, 155.20, 149.99, 141.67, 136.39, 131.94, 129.97, 129.83, 128.00, 127.92, 127.30, 126.86, 126.64, 125.52, 117.64, 22.83, -0.10; HRMS (ESI) m/z calcd. for $C_{21}H_{23}NSi$ [M+H] $^{+}$ = 317.1600, found = 317.1608.

(E)-1-Iodo-3-(1-phenyl-2-(trimethylsilyl)vinyl)isoquinoline (3v)

The title compound was prepared according to the general procedure as a white solid (77.0 mg, 90% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.07–8.06 (m, 1H), 7.60–7.57 (m, 2H), 7.49–7.43 (m, 5H), 7.30–7.29 (m, 2H), 7.02 (s, 1H), -0.08 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 153.03, 152.44, 140.80, 136.63, 134.01, 132.84, 130.95, 130.79, 129.87, 128.63, 128.21, 127.88, 127.58, 119.04, -0.19; HRMS (ESI) m/z calcd. for $C_{20}H_{20}INSi[M+H]^{+}=429.0410$, found = 429.0411.

(*E*)-2-(1-Phenyl-2-(trimethylsilyl)vinyl)pyridine (3w)

The title compound was prepared according to the general procedure as a white solid (36.0 mg, 71% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.63 (d, J = 4.5 Hz, 1H), 7.54–7.51 (m, 1H), 7.40–7.36 (m, 3H), 7.26–7.23 (m, 2H), 7.17 (s, 1H), 7.15–7.12 (m, 1H), 6.95 (d, J = 8.0 Hz, 1H), - 0.1 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.11, 155.18, 149.19, 141.37, 136.35, 133.33, 129.76, 128.07, 127.46, 122.23, 122.16, -2.3; HRMS (ESI) m/z calcd. for $C_{16}H_{20}NSi$ [M+H] $^{+}$ = 254.0360, found = 254.1363.

(E)-2-(1-Phenyl-2-(trimethylsilyl)vinyl)pyrazine (3x)

The title compound was prepared according to the general procedure as a white solid (27.4 mg, 54% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.56 (br, 1H), 8.41 (d, J = 7.0 Hz, 1H), 8.29 (s, 1H), 7.43–7.37 (m, 3H), 7.25–7.24 (m, 2H), 7.18 (s, 1H), -0.08 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 153.52, 152.55, 143.70, 143.49, 142.91, 139.97, 136.54, 129.57, 128.36, 127.94, -0.35; HRMS (ESI) m/z calcd. for $C_{15}H_{19}N_{2}Si$ [M+H] $^{+}$ = 255.1312, found = 255.1315.

(E)-2-(1-Phenyl-2-(trimethylsilyl)vinyl)quinoxaline (3y)

The title compound was prepared according to the general procedure as a white solid (29.1 mg, 48% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.26 (s, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.77–7.70 (m, 2H), 7.45–7.39 (m, 3H), 7.32–7.31 (m, 3H), -0.03 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 153.38, 153.03, 144.52, 141.94, 141.48, 140.11, 138.26, 130.11, 129.73, 129.69, 129.57, 128.96, 128.40, 128.02, -0.23; $C_{19}H_{21}N_2Si$ [M+H] $^{+}$ = 305.1469, found = 305.1474

(*E*)-2-Bromo-6-(1-(p-tolyl)-2-(trimethylsilyl)vinyl)pyridine (3z)

The title compound was prepared according to the general procedure as a white solid (64.9 mg, 94% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.35–7.32 (m, 1H), 7.30–7.28 (m, 2H), 7.19 (d, J = 7.5 Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 6.81 (d, J = 7.5 Hz, 1H), 2.40 (s, 3H), -0.10 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.27, 153.10, 141.87, 138.59, 137.53, 137.28, 135.09, 126.22, 120.80, 21.25, -0.23; HRMS (ESI) m/z calcd. for $C_{17}H_{21}BrNSi [M+H]^{+}$ 346.0621, found = 346.0627.

(E)-2-Bromo-6-(1-(4-methoxyphenyl)-2-(trimethylsilyl)vinyl)pyridine (3aa)

The title compound was prepared according to the general procedure as a white solid (65.7 mg, 91% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.36–7.33 (m, 1H), 7.29 (d, J =

7.5 Hz, 1H), 7.25 (s, 1H), 7.12 (d, J = 8.0 Hz, 2H), 6.91 (d, J = 8.0 Hz, 2H), 6.82 (d, J = 7.5 Hz, 1H), 3.85 (s, 3H), -0.10 (s, 9H); ¹³C NMR (125 MHz, CDCl₃): δ 159.47, 159.14, 152.77, 141.87, 138.60, 135.28, 132.83, 130.83, 126.23, 120.78, 113.54, 55.22, -0.21; HRMS (ESI) m/z calcd. for C₁₇H₂₁BrNOSi [M+H] $^+ = 362.0570$, found = 362.0571.

(E)-2-Bromo-6-(1-(4-fluorophenyl)-2-(trimethylsilyl)vinyl)pyridine (3ab)

The title compound was prepared according to the general procedure as a white solid (52.3 mg, 75% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.38–7.35 (m, 1H), 7.32–7.30 (m, 2H), 7.22–7.17 (m, 2H), 7.10–7.07 (m, 2H), 6.78 (d, J = 7.5 Hz, 1H), -0.10 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 162.40 (d, J = 245.38 Hz), 158.93, 151.99, 142.01, 138.70, 136.49 (d, J = 3.50 Hz), 136.06, 131.37 (d, J = 8.00 Hz), 126.46, 120.62, 115.21 (d, J = 21.38 Hz), -0.28; HRMS (ESI) m/z calcd. for C₁₆H₁₈BrFNSi [M+H] $^{+}$ = 350.0370, found = 350.0373.

(E)-2-Bromo-6-(1-(4-chlorophenyl)-2-(trimethylsilyl)vinyl)pyridine (3ac)

The title compound was prepared according to the general procedure as a white solid (60.6 mg, 83% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.38–7.35 (m, 3H), 7.32–7.30 (m, 2H), 7.15 (d, J = 8.0 Hz, 2H), 6.77 (d, J = 7.5 Hz, 1H), -0.09 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.66, 151.84, 142.02, 139.03, 138.71, 136.14, 133.69, 131.11, 128.47, 126.52, 120.60, -0.24; HRMS (ESI) m/z calcd. for C₁₆H₁₈BrClNSi [M+H] $^{+}$ = 366.0075, found = 366.0076.

(E)-2-Bromo-6-(1-(4-bromophenyl)-2-(trimethylsilyl)vinyl)pyridine (3ad)

The title compound was prepared according to the general procedure as a white solid (74.3 mg, 92% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.52 (d, J = 8.0 Hz, 2H), 7.38–7.35 (m, 1H), 7.32–7.29 (m, 2H), 7.09 (d, J = 8.5 Hz, 2H), 6.77 (d, J = 7.5 Hz, 1H), -0.09 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.57, 151.83, 142.02, 139.51, 138.71, 136.12, 131.43, 126.54, 121.80, 120.60, -0.23; HRMS (ESI) m/z calcd. for $C_{16}H_{18}Br_2NSi [M+H]^+$ = 405.9571, found = 405.9578.

(E)-2-Bromo-6-(1-(naphthalen-1-yl)-2-(trimethylsilyl)vinyl)pyridine (3ae)

The title compound was prepared according to the general procedure as a white solid (68.6 mg, 90% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.89–7.86 (m, 2H), 7.70–7.67 (m, 2H), 7.52–7.44 (m, 2H), 7.37–7.34 (m, 2H), 7.28–7.25 (m, 1H), 7.22–7.18 (m, 1H), 6.54 (d, J = 7.5 Hz, 1H), -0.30 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.52, 150.93, 142.00, 138.89, 137.90, 137.06, 133.50, 132.50, 128.20, 127.67, 126.37, 126.19, 126.16, 125.99, 125.28, 120.66, -0.70; HRMS (ESI) m/z calcd. for $C_{20}H_{21}BrNSi[M+H]$ $^{+}$ = 382.0621, found = 382.0623.

(E)-2-Bromo-6-(1-(naphthalen-2-yl)-2-(trimethylsilyl)vinyl)pyridine (3af)

The title compound was prepared according to the general procedure as a white solid (70.9 mg, 93% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.90–7.83 (m, 3H), 7.73 (s, 1H), 7.54–7.52 (m, 2H), 7.39 (s, 1H), 7.32–7.30 (m, 3H), 6.82–6.78 (m, 1H), -0.12 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.01, 153.06, 142.00, 138.65, 138.11, 135.88, 133.10, 132.72, 128.73, 127.92, 127.82, 127.79, 127.71, 126.40, 126.36, 126.17, 120.98, -0.18; HRMS (ESI) m/z calcd. for $C_{20}H_{21}BrNSi$ [M+H] $^{+}$ = 382.0621, found = 382.0623.

(E)-2-Bromo-6-(1-(phenanthren-9-yl)-2-(trimethylsilyl)vinyl)pyridine (3ag)

The title compound was prepared according to the general procedure as a white solid (65.5 mg, 76% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.73 (d, J = 8.0 Hz, 2H), 7.88 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.71–7.68 (m, 2H), 7.65–7.62 (m, 3H), 7.48–7.45 (m, 1H), 7.28–7.25 (m, 1H), 7.19–7.16 (m, 1H), 6.65 (d, J = 8.0 Hz, 1H), -0.25 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.39, 151.20, 142.04, 138.90, 137.36, 136.52, 131.48, 131.31, 130.34, 130.30, 128.63, 128.54, 127.11, 126.91, 126.75, 126.73, 126.46, 122.86, 122.66, 120.69, -0.51; HRMS (ESI) m/z calcd. for C₂₄H₂₃BrNSi [M+H] $^{+}$ = 432.0778, found = 432.0780.

(E)-2-(1-(Anthracen-9-yl)-2-(trimethylsilyl)vinyl)-6-bromopyridine (3ah)

The title compound was prepared according to the general procedure as a white solid (74.1 mg, 86% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.50 (s, 1H), 8.04–8.03 (m, 3H), 7.93 (d, J = 8.5 Hz, 2H), 7.47–7.44 (m, 2H), 7.39–7.36 (m, 2H), 7.28–7.26 (m, 1H), 7.13–7.10 (m, 1H), 6.30 (d, J = 7.5 Hz, 1H), -0.56 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 158.21, 148.37, 142.13, 139.20, 139.05, 134.44, 131.35, 130.42, 128.47, 126.96,

126.53, 125.76, 125.36, 120.54, -1.27; HRMS (ESI) m/z calcd. for $C_{24}H_{23}BrNSi$ [M+H] $^{+}$ = 432.0778, found = 432.0780.

(E)-2-(1-(9H-Fluoren-2-yl)-2-(trimethylsilyl)vinyl)-6-bromopyridine (3ai)

The title compound was prepared according to the general procedure as a white solid (79.8 mg, 95% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.83–7.79 (m, 2H), 7.56 (d, J = 7.5 Hz, 2H), 7.42–7.38 (m, 2H), 7.35–7.29 (m, 4H), 7.22 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 7.5 Hz, 1H), -0.10 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.29, 153.39, 143.36, 143.16, 141.96, 141.36, 141.17, 139.15, 138.65, 135.36, 128.42, 126.86, 126.39, 126.33, 125.10, 120.93, 119.95, 119.58, 36.92, -0.15; HRMS (ESI) m/z calcd. for $C_{24}H_{23}BrNSi [M+H]^{+}$ = 420.0778, found = 432.0780.

(E)-2-Bromo-6-(1-(9,9-dimethyl-9H-fluoren-2-yl)-2-(trimethylsilyl)vinyl)pyridine (3aj)

The title compound was prepared according to the general procedure as a white solid (86.0 mg, 96% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.77–7.73 (m, 2H), 7.46 (d, J = 7.0 Hz, 1H), 7.38–7.30 (m, 6H), 7.18 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 7.5 Hz, 1H), 1.51 (s, 6H), -0.09 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.23, 153.70, 153.64, 153.49, 141.96, 139.61, 138.84, 138.69, 138.62, 135.38, 128.47, 127.37, 127.05, 126.33, 124.21, 122.66, 120.90, 120.02, 119.69, 46.86, 27.06, -0.20; HRMS (ESI) m/z calcd. for $C_{25}H_{27}BrNSi [M+H]^{+}$ = 448.1091, found = 448.1094.

(Z)-2-Bromo-6-(1-(furan-2-yl)-2-(trimethylsilyl)vinyl)pyridine (3ak)

The title compound was prepared according to the general procedure as a white solid (59.2 mg, 92% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.50–7.47 (m, 2H), 7.39 (d, J = 7.5 Hz, 1H), 7.26 (d, J = 7.5 Hz, 1H), 6.65 (s, 1H), 6.47–6.46 (m, 1H), 6.36 (d, J = 3.0 Hz, 1H), 0.13 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.71, 152.83, 142.74, 141.90, 141.52, 138.67, 137.09, 126.82, 121.14, 111.48, 110.84, 0.03; HRMS (ESI) m/z calcd. for $C_{14}H_{17}BrNOSi$ [M+H] $^{+}$ = 322.0257, found = 322.0258.

(Z)-2-Bromo-6-(1-(thiophen-2-yl)-2-(trimethylsilyl)vinyl)pyridine (3al)

The title compound was prepared according to the general procedure as a white solid (64.9 mg, 96% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.41–7.38 (m, 1H), 7.36–7.35 (m, 2H), 7.32 (d, J = 8.0 Hz, 1H), 7.06–7.01 (m, 2H), 6.96–6.95 (m, 1H), -0.02 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 159.04, 145.41, 141.72, 141.09, 139.68, 138.76, 128.22, 126.75, 126.56, 126.01, 120.56, -0.50; HRMS (ESI) m/z calcd. for C₁₄H₁₇BrNSSi [M+H] $^{+}$ = 338.0029, found = 338.0030.

(E)-2-Bromo-6-(1-(thiophen-3-yl)-2-(trimethylsilyl)vinyl)pyridine (3am)

The title compound was prepared according to the general procedure as a white solid (64.2 mg, 95% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.39–7.34 (m, 2H), 7.32–7.30 (m, 2H), 7.16–7.15 (m, 1H), 6.95 (d, J = 4.5 Hz, 1H), 6.87 (d, J = 7.5 Hz, 1H), -0.06 (s,

9H); 13 C NMR (125 MHz, CDCl₃): δ 158.77, 147.93, 141.90, 140.68, 138.74, 136.72, 129.22, 126.45, 125.50, 124.35, 120.46, -0.40; HRMS (ESI) m/z calcd. for $C_{14}H_{17}BrNSSi\left[M+H\right]^{+}$ = 338.0029, found = 338.0030.

(E)-2-Bromo-6-(1-cyclopentyl-2-(trimethylsilyl)vinyl)pyridine (3an)

The title compound was prepared according to the general procedure as a white solid (59.6 mg, 92% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.45–7.42 (m, 1H), 7.30–7.27 (m, 2H), 5.89 (s, 1H), 3.10–3.03 (s, 1H), 1.86–1.77 (m, 6H), 1.60–1.57 (m, 2H), 0.19 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 162.74, 158.68, 140.21, 138.16, 133.25, 125.65, 121.33, 46.34, 31.95, 26.40, 0.24; HRMS (ESI) m/z calcd. for C₁₅H₂₃BrNSi [M+H] $^{+}$ = 324.0778, found = 324.0780.

(E)-2-Bromo-6-(1-(trimethylsilyl)prop-1-en-2-yl)pyridine (3ao)

The title compound was prepared according to the general procedure as a white solid (58.4 mg, 93% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.50–7.47 (m, 1H), 7.43–7.41 (m, 1H), 7.33–7.32 (m, 1H), 6.57 (s, 1H), 2.24 (s, 3H), 0.21 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 161.06, 149.05, 141.31, 138.57, 132.25, 126.15, 118.33, 19.24, -0.19; HRMS (ESI) m/z calcd. for $C_{14}H_{25}BrNSi$ [M+H] $^{+}$ = 314.0934, found = 314.0933.

(E)-2-Bromo-6-(1-(trimethylsilyl)hex-1-en-2-yl)pyridine (3ap)

The title compound was prepared according to the general procedure as a white solid (54.3 mg, 87% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.49–7.46 (m, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.31 (d, J = 7.5 Hz, 1H), 6.32 (s, 1H), 2.69–2.66 (m, 2H), 1.36–1.35 (m, 4H), 0.90 (t, J = 6.5 Hz, 3H), 0.20 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 161.18, 155.06, 141.31, 138.54, 132.25, 126.04, 119.21, 33.04, 31.75, 22.94, 13.97, 0.11; HRMS (ESI) m/z calcd. for $C_{14}H_{23}BrNSi$ [M+H] $^{+}$ = 312.0778, found = 312.0782.

(E)-2-Bromo-6-(5-((tert-butyldimethylsilyl)oxy)-1-(trimethylsilyl)pent-1-en-2-yl) pyridine (3aq)

The title compound was prepared according to the general procedure as a white solid (77.0 mg, 90% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.48–7.45 (m, 1H), 7.42 (d, J = 7.5 Hz, 1H), 7.31 (d, J = 7.5 Hz, 1H), 6.40 (s, 1H), 3.64 (t, J = 6.5 Hz, 2H), 2.75–2.72 (m, 2H), 1.63–1.59 (m, 2H), 0.90 (s, 9H), 0.21 (s, 9H), 0.05 (s, 6H); 13 C NMR (125 MHz, CDCl₃): δ 160.70, 154.26, 141.35, 138.56, 132.57, 126.12, 119.20, 63.15, 32.64, 29.78, 25.98, 18.35, 0.06, -5.32; HRMS (ESI) m/z calcd. for $C_{19}H_{35}BrNSi_{2}[M+H]^{+}$ = 428.1435, found = 428.1437.

(E)-2-Bromo-6-(1-phenyl-2-(triethylsilyl)vinyl)pyridine (3ar)

The title compound was prepared according to the general procedure as a white solid (67.3 mg, 90% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.37–7.36 (m, 3H), 7.35–7.32 (m, 1H), 7.29–7.28 (m, 1H), 7.26 (s, 1H), 7.22–7.21 (m, 2H), 6.77 (d, J = 7.5 Hz, 1H), 0.85 (t, J = 8.0 Hz, 9H), 0.36 (q, J = 8.0 Hz, 1H); 13 C NMR (125 MHz, CDCl₃): δ 159.13, 153.77, 141.90, 140.86, 138.58, 132.64, 129.56, 128.08, 127.65, 126.25,

120.74, 7.52, 4.11; HRMS (ESI) m/z calcd. for $C_{19}H_{25}BrNSi_2$ [M+H] $^+$ = 374.0934, found = 374.0936.

(E)-2-Bromo-6-(2-(tert-butyldimethylsilyl)-1-phenylvinyl)pyridine (3as)

The title compound was prepared according to the general procedure as a white solid (52.3 mg, 70% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.39–7.31 (m, 5H), 7.29–7.28 (m, 1H), 7.21–7.20 (m, 2H), 6.76 (d, J = 7.0 Hz, 1H), 0.93 (s, 9H), -0.30 (s, 6H); 13 C NMR (125 MHz, CDCl₃): δ 159.14, 153.74, 141.90, 140.67, 138.58, 132.31, 129.85, 128.11, 127.52, 126.26, 120.70, 26.73, 17.03, -5.14; HRMS (ESI) m/z calcd. for $C_{19}H_{25}BrNSi_{2}$ [M+H] $^{+}$ = 374.0934, found = 374.0936.

1,4-Bis((E)-1-(6-bromopyridin-2-yl)-2-(trimethylsilyl)vinyl)benzene (3at)

The title compound was prepared according to the general procedure as a white solid (104.1 mg, 89% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.34–7.31 (m, 2H), 7.28–7.27 (m, 4H), 7.20 (br, 4H), 6.77 (d, J = 7.5 Hz, 2H), - 0.08 (s, 18H); 13 C NMR (125 MHz, CDCl₃): δ 159.04, 152.70, 142.00, 140.13, 138.69, 135.55, 129.74, 126.43, 120.59, - 0.07; HRMS (ESI) m/z calcd. for C₂₆H₃₁Br₂N₂Si₂ [M+H] $^{+}$ = 585.0387, found = 585.0388.

1,3-Bis((E)-1-(6-bromopyridin-2-yl)-2-(trimethylsilyl)vinyl)benzene (3au)

The title compound was prepared according to the general procedure as a white solid (79.6 mg, 68% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.46–7.43 (m, 1H), 7.37–7.34 (m, 2H), 7.31–7.30 (m, 2H), 7.26–7.25 (m, 3H), 7.22 (s, 2H), 7.03 (s, 1H), 6.89 (d, J = 7.5 Hz, 2H), -0.07 (s, 18H); 13 C NMR (125 MHz, CDCl₃): δ 159.25, 152.98, 141.92, 140.86, 138.53, 135.51, 130.59, 129.27, 128.26, 126.46, 120.84, 0.01; HRMS (ESI) m/z calcd. for $C_{26}H_{31}Br_{2}N_{2}Si_{2}$ [M+H] $^{+}$ = 585.0387, found = 585.0388.

2,5-Bis((Z)-1-(6-bromopyridin-2-yl)-2-(trimethylsilyl)vinyl)thiophene (3av)

The title compound was prepared according to the general procedure as a white solid (113.9 mg, 64% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.44–7.41 (m, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.29 (s, 2H), 7.16 (d, J = 7.5 Hz, 2H), 6.93 (s, 2H), 0.09 (s, 18H); 13 C NMR (125 MHz, CDCl₃): δ 159.22, 145.45, 142.39, 141.74, 139.55, 138.70, 128.05, 126.69, 120.43, -0.17; HRMS (ESI) m/z calcd. for $C_{24}H_{29}Br_2N_2Si_2[M+H]^+$ = 590.9951, found = 890.9954.

$2\text{-Bromo-}6\text{-}((E)\text{-}5\text{-}(((3R,8S,9S,10R,13R,14S,17R)\text{-}10,13\text{-}dimethyl\text{-}17\text{-}((R)\text{-}6\text{-}methyl heptan-}2\text{-}Yl)\text{-}2,3,4,7,8,9,10,11,12,13,14,15,16,17\text{-}tetradecahydro-}1\text{H-cyclopenta[a] phenanthren-}3\text{-}yl)oxy)\text{-}1\text{-}(trimethylsilyl)pent-}1\text{-}en-}2\text{-}yl)pyridine (3aw)$

The title compound was prepared according to the general procedure as a white solid (117.3 mg, 86% yield). 1 H NMR (500 MHz, CDCl₃): δ 7.48–7.45 (m, 1H), 7.41 (d, J = 7.5 Hz, 1H), 7.31 (d, J = 7.5 Hz, 1H), 6.36 (s, 1H), 5.34–5.33 (m, 1H), 3.47 (t, J = 6.5 Hz, 2H), 3.15–3.10 (m, 1H), 2.76–2.73 (m, 2H), 2.36–2.33 (m, 1H), 2.20–2.15 (m, 3H),

2.02-1.95 (m, 2H), 1.90-1.79 (m, 3H), 1.67-1.25 (m, 15H), 1.16-0.86 (m, 20H), 0.68 (s, 3H), 0.21 (s, 9H); 13 C NMR (125 MHz, CDCl₃): δ 160.87, 154.36, 141.31, 141.08, 138.57, 132.71, 126.11, 121.44, 119.30, 78.96, 67.62, 56.79, 56.16, 50.21, 42.32, 39.79, 39.51, 39.19, 37.25, 36.90, 36.19, 35.78, 31.96, 31.90, 30.91, 30.06, 29.85, 28.46, 28.23, 28.00, 24.29, 23.82, 22.81, 22.55, 21.07, 19.38, 18.71, 11.85, 0.09; HRMS (ESI) m/z calcd. for C₄₀H₆₅BrNSi [M+H] $^+$ = 682.4013, found = 682.4015.

(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(6-(1-phenylvinyl)pyridin-3-yl)-2,3,4, 7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol (3ax)

The title compound was prepared according to the general procedure as a white solid (68.7 mg, 76% yield). 1 H NMR (500 MHz, CDCl₃): δ 8.67 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.37–7.33 (m, 5H), 7.19 (d, J = 8.0 Hz, 1H), 6.03 (br, 1H), 6.01 (s, 1H), 5.56 (s, 1H), 5.39 (d, J = 5.0 Hz, 1H), 3.54 (br, 1H), 2.35–2.24 (m, 3H), 2.10–2.05 (m, 3H), 1.87–1.85 (m, 2H), 1.79–1.74 (m, 3H), 1.71–1.63 (m, 3H), 1.53–1.47 (m, 3H), 1.13–1.04 (m, 8H); 13 C NMR (125 MHz, CDCl₃): δ 156.39, 151.51, 148.95, 147.40, 141.13, 140.50, 133.78, 131.64, 129.18, 128.50, 128.25, 127.78, 122.14, 121.35, 117.26, 71.71, 57.52, 50.34, 47.29, 42.29, 37.17, 36.69, 35.29, 31.82, 31.62, 31.51, 30.43, 20.89, 19.33, 16.59; HRMS (ESI) m/z calcd. for C₃₂H₃₈NO [M+H] $^{+}$ = 452.2948, found = 452.2951.


$$_{NC}$$
 $_{NC}$ $_{NC$


Scheme S1. Ineffect substrates for the present C–H alkenylation by **Sc-4**.


References

- (a) X.-Y. Jin, C.-S. Wu, A.-D. Liu, L. Liu, L. Cheng, *Synthesis*, **2022**, *54*, 1643. (b)
 T. X. Neenan, G. M. Whitesides, *J. Org. Chem.*, **1988**, *53*, 2489.
- (a) L. E. Manzer, *J. Am. Chem. Soc.*, 1978, 100, 8068. (b) M. Nishiura, J. Baldamus, T. Shima, K. Mori, Z. Hou, *Chem. Eur. J.*, 2011, 17, 5033. (c) T. Shima, M. Nishiura, Z. Hou, *Organometallics*, 2011, 30, 2513. (d) X. Li, M. Nishiura, K. Mori, T. Mashiko, Z. Hou, *Chem. Commun.*, 2007, 4137.


IV NMR spectra















3.09 1.98 1.00 1.00


10


zw-84-22-3c


0 1 80.6

ppm























130 120





170 160


140 130 120





Ó


ppm








































Ó


ppm



















Ó


ppm

170 160 150 140 130 120
























ppm



130


120 110


100





ppm































170 160 150

140 130

120

110 100

90

70

40 30

50

10 0

-10

